Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma.

Published

Journal Article

Pediatric high-grade astrocytomas (HGAs) account for 15-20% of all pediatric central nervous system tumors. These neoplasms predominantly involve the supratentorial hemispheres or the pons--diffuse intrinsic pontine gliomas (DIPG). Assumptions that pediatric HGAs are biologically similar to adult HGAs have recently been challenged, and the development of effective therapeutic modalities for DIPG and supratentorial HGA hinges on a better understanding of their biological properties. Here, 20 pediatric HGAs (9 DIPGs and 11 supratentorial HGAs) were subject to gene expression profiling following approval by the research ethics board at our institution. Many of these tumors showed expression signatures composed of genes that promote G1/S and G2/M cell cycle progression. In particular, Aurora kinase B (AURKB) was consistently and highly overexpressed in 6/9 DIPGs and 8/11 HGAs. Array data were validated using quantitative real-time PCR and immunohistochemistry, as well as cross-validation of our data set with previously published series. Inhibition of Aurora B activity in DIPG and in pediatric HGA cell lines resulted in growth arrest accompanied by morphological changes, cell cycle aberrations, nuclear fractionation and polyploidy as well as a reduction in colony formation. Our data highlight Aurora B as a potential therapeutic target in DIPG.

Full Text

Cited Authors

  • Buczkowicz, P; Zarghooni, M; Bartels, U; Morrison, A; Misuraca, KL; Chan, T; Bouffet, E; Huang, A; Becher, O; Hawkins, C

Published Date

  • May 2013

Published In

Volume / Issue

  • 23 / 3

Start / End Page

  • 244 - 253

PubMed ID

  • 22971244

Pubmed Central ID

  • 22971244

Electronic International Standard Serial Number (EISSN)

  • 1750-3639

International Standard Serial Number (ISSN)

  • 1015-6305

Digital Object Identifier (DOI)

  • 10.1111/j.1750-3639.2012.00633.x

Language

  • eng